



## **Quanta to Exhibit at the 11<sup>th</sup> UK Annual Dialysis Conference**

**Alcester, Warwickshire, UK, 31 August 2018:** Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions for clinic and home settings, today announces that the Company will be exhibiting at the 11<sup>th</sup> UK Annual Dialysis Conference, taking place from Thursday 20<sup>th</sup> to Friday 21<sup>st</sup> September 2018, at the Lowry Hotel in Manchester, UK.

The UK Annual Dialysis Conference theme for 2018 is ‘Advancing Dialysis: Now and for the Future’ and will focus on clinical challenges, innovative solutions and future advances in dialysis care. Quanta will exhibit the new look of its personal haemodialysis system, SC+, which it plans to launch in 2019. SC+ is designed to give patients flexibility and to empower them to take control of their dialysis, enabling them to fit treatment around everyday life.

In addition, Quanta will be hosting a workshop on Thursday 20<sup>th</sup> September from 08:30 to 09:30am during which Professor John Agar, Clinical Conjoint Professor of Medicine at Deakin University School of Medicine and the Geelong Hospital, Barwon Health and a member of Quanta’s Medical Advisory Board will, in a presentation entitled: ‘Home Haemodialysis Down Under: Making the Most of Home Therapies’, discuss how Australia and New Zealand have managed to achieve the highest regional adoption rates for home haemodialysis and how SC+ can support the expansion of home dialysis in the UK. Following the seminar, there will be an opportunity, led by Quanta’s clinical nursing team, which will enable attendees to have a hands-on demonstration of SC+.

If you would like to register to attend the free workshop, please RSVP to [David.bond@quantadt.com](mailto:David.bond@quantadt.com).

If you would like to arrange a meeting with John E. Milad, Chief Executive Officer, or Peter Hoyer, Chief Commercial Officer, at the conference, please contact [enquiries@quantadt.com](mailto:enquiries@quantadt.com).

**-ENDS-**

**For more information about Quanta, please contact:**

**Quanta**

John E. Milad,  
Chief Executive Officer

T: +44 (0)1789 400043

E: [enquiries@quantadt.com](mailto:enquiries@quantadt.com)

**Consilium Strategic Communications**

Amber Fennell / Matthew Neal / Lindsey Neville

T: +44 (0)203 709 5708

E: [quanta@consilium-comms.com](mailto:quanta@consilium-comms.com)

**About SC+**

SC+ is a unique small, simple and powerful haemodialysis system that supports patients across the continuum of care, from the clinic to the home. SC+ provides clinical efficacy and high flow rates compatible with traditional treatment regimens used in-centre. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The small form factor and simple-to-use design are intended to enable a broader range of users across a wide range of settings.

**About Quanta**

Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use both in the clinic and the home. Quanta's lead product SC+ is designed to empower dialysis patients by giving them greater flexibility, convenience and control over the delivery of their life-sustaining renal replacement therapy. Quanta is based in Alcester, UK, and was founded in 2008 as a spin out from IMI plc. The company has attracted funding from a group of leading investors, including: Stage Capital (formerly NBGI Ventures), Wellington Partners, Seroba Life Sciences, b-to-v Partners, ALIAD, CITA, Seventure Partners and Kuwait Life Sciences Company, as well as founding partner IMI plc.

For more information, please visit: [www.quantadt.com](http://www.quantadt.com).